Fenoldopam in critically ill patients with early renal dysfunction. A crossover study.
BACKGROUND
Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an option to prevent further damage.


METHODS
We performed a randomized, double-blinded, prospective crossover study in 17 patients admitted to our trauma intensive care unit (ICU) with evidence of impaired renal function. Patients were randomized to a 24-h intravenous infusion of low-dose fenoldopam or placebo. When the infusion of fenoldopam or placebo was completed, patients underwent a 24-h "washout" period in which no study intervention was performed. This sequence was repeated in each patient with the opposite agent, so each patient served as his own control. Four-hour creatinine collections were taken during the last 4 h of each infusion and washout periods to determine creatinine clearance changes during and after the administration of the study drug.


RESULTS
The creatinine clearance was higher with fenoldopam infusion than with placebo infusion (P = 0.045). The FENa was not significantly different.


CONCLUSIONS
Our study showed that low-dose Fenoldopam increases creatinine clearance in the critically ill with renal insufficiency. Fenoldopam may be a useful drug in ICU patients with early renal dysfunction.
Department of Anesthesiology, Perioperative Medicine and Pain Management, Leonard M. Miller School of Medicine, University of Miami, FL, USA.
Miguel
M
Cobas
Gian
G
Paparcuri
Maria
M
De La Pena
Gaston
G
Cudemus
Erik
E
Barquist
Albert
A
Varon
D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000503:physiopathology; D000328:Adult; D000368:Aged; D016638:Critical Illness; D018592:Cross-Over Studies; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004311:Double-Blind Method; D018818:Fenoldopam / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies
D018491:Dopamine Agonists; D018818:Fenoldopam